IN

Indaptus Therapeutics IncNASDAQ INDP Stock Report

Last reporting period 30 Sep, 2023

Updated 26 Nov, 2024

Last price

Market cap $B

0.012

Micro

Exchange

XNAS - Nasdaq

INDP Stock Analysis

IN

Uncovered

Indaptus Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.012

Dividend yield

Shares outstanding

8.401 B

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York. The company went IPO on 2012-09-07. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

View Section: Eyestock Rating